Management of drug-induced liver disease

Current Gastroenterology Reports

Volumn 3, Issue 1, 2001, Pages 38-48

  Marino, Gustavo ^b   Zimmerman, Hyman J ^b   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

Acute Liver Failure; APAP; Fulminant Hepatic Failure; Hepatic Injury; Juvenile Rheumatoid Arthritis

Indexed keywords

ANALGESIC AGENT; IRON; PARACETAMOL;

CHEMICALLY INDUCED DISORDER; CHOLESTASIS; DRUG EFFECT; HUMAN; INTOXICATION; LIVER; LIVER DISEASE; LIVER FAILURE; REVIEW;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; CHOLESTASIS; HUMANS; IRON; LIVER; LIVER DISEASES; LIVER FAILURE; OVERDOSE;

EID: 0008842794     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-001-0039-y     Document Type: Article

References (121)

1. Popper H, Rubin E, Gardiol D, et al.: Drug induced liver disease: a penalty for progress. Arch Int Med 1965, 115:128–136.
2. Lewis JH: Drug-induced liver disease. Med Clin North Am 2000, 84:1275–1311. A comprehensive review of all aspects of drug-induced hepatotoxicity. DOI: 10.1016/S0025-7125(05)70287-X
3. O’Grady JG: Paracetamol-induced acute liver failure: prevention and management. J Hepatol 1997, 26:41–46. DOI: 10.1016/S0168-8278(97)82332-X
4. Zimmerman HJ: Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, edn 2. Philadelphia: Lippincott-Williams & Wilkins; 1999. The recently published second edition of this classic textbook provides the most comprehensive overview of drug-induced liver disease available.
5. Liebelt E: Iron. In Clinical Management of Poisoning and Drug Overdose, edn 3. Edited by Haddad L, Shannon MW, Winchester JF. Philadelphia: WB Saunders; 1998:757–766.
6. Zimmerman HJ: Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981, 141:333–342. DOI: 10.1001/archinte.141.3.333
7. Ostapowicz G, Fontana RJ, Navarro VJ, et al.: Use of liver transplantation in patients with acute liver failure [abstract]. Hepatology 2000, 32:215A.
8. Makin AJ, Wendon J, Williams R: A 7-year experience of severe paracetamol-induced hepatotoxicity (1987-1983). Gastroenterology 1995, 109:1907–1916. DOI: 10.1016/0016-5085(95)90758-0
9. Zimmerman HJ, Maddrey WC: Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of a therapeutic misadventure. Hepatology 1995, 22:767–774.
10. Schiødt FV, Rochling FA, Casey DL, et al.: Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997, 337:1112–1117. DOI: 10.1056/NEJM199710163371602
11. Heubi HE, Barbacci MB, Zimmerman HJ: Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children. J Pediatr 1998, 132:22–27. One of the first reports drawing attention to the issue of unintentional acetaminophen overdose in infants and young children. DOI: 10.1016/S0022-3476(98)70479-2
12. Rumack BH: Acetaminophen overdose in young children. Am J Dis Child 1984, 138:428–433.
13. Miles FK, Kamath R, Dorney SF, et al.: Accidental paracetamol overdosing and fulminant hepatic failure in children. Med J Aust 1999, 171:472–475.
14. Caravati EM: Unintentional acetaminophen ingestion in children and the potential for hepatotoxicity. J Toxicol Clin Toxicol 2000, 38:291–296. This article provides a useful template for evaluating acetaminophen overdose in young children, with specific recommendations for early referral and treatment. DOI: 10.1081/CLT-100100934
15. Larson AM, Ostapowicz G, Fontana RJ, et al., for the Acute Liver Failure Study Group: Outcome of acetaminophen-induced liver failure in the USA in suicidal vs. accidental overdose: preliminary results of a prospective multi-center trial [abstract]. Hepatology 2000, 32:396A.
16. Rumack RH, Mathew H: Acetaminophen poisoning and toxicity. Pediatrics 1975, 55:871–876.
17. Prescott LF: Paracetamol overdosage: pharmacological considerations and clinical management. Drugs 1983, 25:290–314.
18. Vale JA, Proudfoot AT: Paracetamol (acetaminophen) poisoning. Lancet 1995, 346:547–552. DOI: 10.1016/S0140-6736(95)91385-8
19. Buckley NA, Whyte IM, O’Connell DL, Dawson AH: Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol 1999, 37:753–757. Activated charcoal can still be effective when given up to 24 hours after acetaminophen overdose. DOI: 10.1081/CLT-100102452
20. Mitchell JR, Jollow DJ, Potter WZ, et al.: Acetaminophen induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 1973, 187:185–194.
21. Mitchell JR, Thorgeirsson SS, Potter WZ, et al.: Acetaminophen induced hepatic necrosis. V. Protective role of glutathion in man and rationale for therapy. Clinical Pharmacol Ther 1974, 16:676–684.
22. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH: Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. N Engl J Med 1988, 319:1557–1562. DOI: 10.1056/NEJM198812153192401
23. Keays R, Harrison PM, Wendon JA, et al.: Intravenous acetylcysteine in paracetamol induced hepatic failure: a prospective controlled trial. Br Med J 1991, 303:1026–1029.
24. Smilkstein MJ, Bronstein AC, Linden C, et al.: Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med 1991, 20:1058–1063. DOI: 10.1016/S0196-0644(05)81352-6
25. Woo OF, Mueller PD, Olson KR, et al.: Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann Emerg Med 2000, 35:363–368. Shorter-duration treatment with N-acetylcysteine can be considered in patients where no evidence of hepatotoxicity is seen in the first 36 hours after an overdose. Two thirds of the patients in this reported study were successfully treated for less than 36 hours. DOI: 10.1016/S0196-0644(00)70055-2
26. Buckley NA, Whyte IM, O’Connell DL, Dawson AH: Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? J Toxicol Clin Toxicol 1999, 37:759–767. Although it is available for IV administration, intravenous N-acetylcysteine leads to adverse reactions, including anaphylaxis, in a significant percentage of patients and is not approved for use in the United States. DOI: 10.1081/CLT-100102453
27. Bateman DN, Woodhouse KW, Rawlins MD: Adverse reactions to N-acetylcysteine. Human Toxicol 1984, 3:393–398.
28. Mant TGK, Tempowski JH, Volans GN, et al.: Adverse reactions to acetylcysteine and effects of overdose. Br Med J 1984, 289:217–219.
29. Tenenbein M: Hypersensitivity-like reactions to N-acetylcysteine. Vet Hum Toxicol 1984, 26:3–5.
30. Donovan JW, Proudfoot AT, Prescott LF: Adverse effects of intravenous N-acetylcysteine [abstract]. Vet Hum Toxicol 1986, 28:487.
31. Dawson AH, Henry DA, McEwen J: Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust 1989, 150:329–331.
32. Chan TYK, Critchley JAJH: Adverse reactions to intravenous N-acetylcysteine in Chinese patients with paracetamol (acetaminophen) poisoning. Hum Exp Toxicol 1994, 13:542–544.
33. Yip L, Dart RC, Hurlbut KM: Intravenous administration of oral N-acetylcysteine. Crit Care Med 1998, 26:40–43. DOI: 10.1097/00003246-199801000-00014
34. McLean AEM, Day PA: The effect of diet on the toxicity of paracetamol and the safety of paracetamol-methionine mixtures. Biochem Pharmacol 1975, 24:37–42. DOI: 10.1016/0006-2952(75)90310-X
35. Vale JA, Meredith TJ, Goulding R: Treatment of acetaminophen poisoning: the use of oral methionine. Arch Intern Med 1981, 141:394–396. DOI: 10.1001/archinte.141.3.394
36. Saunders JB, Wright N, Lewis KO: Predicting outcome of paracetamol poisoning by using 14 C-aminopyrine breath test. Br Med J 1980, 280:279–280.
37. Speeg KV: Potential use of cimetidine for treatment of acetaminophen overdose. Pharmacotherapy 1987, 7:125S-133S.
38. Clark R, Thompson RPH, Borirakchanyavat V, et al.: Hepatic damage and death from overdose of paracetamol. Lancet 1973, 1:66–70. DOI: 10.1016/S0140-6736(73)90466-2
39. Speeg KV, Bay MK: Prevention and treatment of drug induced liver disease. Gastroenterol Clin North Am 1995, 24:1047–1064.
40. Zed PJ, Krenzelok EP: Treatment of acetaminophen overdose. Am J Health Syst Pharm 1999, 56:1081–1091.
41. Bruck R, Frenkel D, Shirin H, et al.: Hypothyroidism protects rat liver from acetaminophen hepatotoxicity. Dig Dis Sci 1999, 44:1228–1235. DOI: 10.1023/A:1026652913347
42. O’Grady JG: Paracetamol induced acute liver failure: prevention and management. J Hepatol 1997, 26:41–46. DOI: 10.1016/S0168-8278(97)82332-X
43. Rolando N, Wade JJ, Stangou A, et al.: Prospective study comparing the efficacy of prophylactic parenteral antimicrobials, with or without enteral decontamination, in patients with acute liver failure. Liver Transpl Surg 1996, 2:8–13. DOI: 10.1002/lt.500020103
44. O’Grady J, Alexander G, Hayllar K, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989, 97:439–445.
45. Mitchell I, Bihari D, Chang R, et al.: Earlier identification of patients at risk from acetaminophen-induced acute liver failure. Crit Care Med 1998, 26:279–284. DOI: 10.1097/00003246-199802000-00026
46. Bernal W, Wendon J, Rela M, et al.: Use and outcome of liver transplantation in acetaminophen-induced acute liver failure. Hepatology 1998, 27:1050–1055. Close psychiatric follow-up is important for patients who have attempted suicide with acetaminophen. Another overdose or deliberate self-harm has been reported in 12% of survivors in this series from King’s College. DOI: 10.1002/hep.510270421
47. O’Grady J, Wendon J, Tan K, et al.: Liver transplantation for acute liver failure. Hepatology 1995, 2:1018–1024.
48. Nyberg SL, Misra SP: Hepatocyte liver-assist systems: a clinical update. Mayo Clinic Proc 1998, 73:765–771.
49. Wilkinson AH, Ash SR, Nissenson AR: Hemodiabsorption in treatment of hepatic failure. J Transplant Coord 1998, 8:43–50.
50. Higgins RM, Goldsmith DJ, MacDiarmid-Gordon A, et al.: Treating paracetamol overdose by charcoal haemoperfusion and long-hours high-flux dialysis. QJM 1996, 89:297–306.
51. Chrungoo VJ, Singh K, Singh J: Silymarin mediated differential modulation of toxicity induced by carbon tetrachloride, paracetamol and D-galactosamine in freshly isolated rat hepatocytes. Indian J Exp Biol 1997, 35:611–617.
52. Jafri MA, Jalis Subhani M, Javed K, Singh S: Hepatoprotective activity of leaves of Cassia occidentalis against paracetamol and ethyl alcohol intoxication in rats. J Ethnopharmacol 1999, 66:355–361. DOI: 10.1016/S0378-8741(99)00037-9
53. Karan M, Vasisht K, Handa SS: Antihepatotoxic activity of Swertia chirata on paracetamol and galactosamine induced hepatotoxicity in rats. Phytother Res 1999, 13:95–101. DOI: 10.1002/(SICI)1099-1573(199903)13:2<95::AID-PTR379>3.0.CO;2-4
54. Committee on Safety of Medicines, Medicines Control Agency: Paracetamol and aspirin. Curr Prob Pharmacovigilance 1997, 23:9.
55. Turvill JL, Burroughs AK, Moore KP: Change in occurrence of paracetamol overdose in UK after introduction of blister packs. Lancet 2000, 355:2048–2049. See annotation below. DOI: 10.1016/S0140-6736(00)02355-2
56. Prince MI, Thomas SHL, James OFW, Hudson M: Reduction in incidence of severe paracetamol poisoning. Lancet 2000, 355:2047–2048. See annotation below. DOI: 10.1016/S0140-6736(00)02354-0
57. Poulin C: Prevention of paracetamol poisoning. Lancet 2000, 355:2009–2010. These three reports document a significant reduction in acetaminophen overdose in the United Kingdom following legislation that limited the number of APAP tablets that could be purchased at any one time using blister-packs containing sixteen 500-mg tablets. DOI: 10.1016/S0140-6736(00)02342-4
58. Kearns GL, Leeder JS, Wasserman GS: Acetaminophen intoxication during treatment: what you don’t know can hurt you. Clin Pediatr 2000, 39:133–144.
59. Paracetamol, methionine: Pameton. Drug Ther Bull 1987, 25:99–100.
60. Zimmerman HJ: Acetaminophen hepatotoxicity. Clin Liver Dis 1998, 2:523–541. DOI: 10.1016/S1089-3261(05)70025-8
61. Prescott LF: Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000, 49:291–301. DOI: 10.1046/j.1365-2125.2000.00167.x
62. Whitcomb DC, Block GD: Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994, 272:1845–49. DOI: 10.1001/jama.272.23.1845
63. Harrison PM, Wendon JA, Gimson AE, et al.: Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant liver failure. N Engl J Med 1991, 324:1852–1857. DOI: 10.1056/NEJM199106273242604
64. Mills KC, Curry SC: Acute iron poisoning. Emerg Med Clin North Am 1994, 12:397–413.
65. Centers for Disease Control: Toddler death resulting from ingestion of iron supplements: Los Angeles 1992–1993. MMWR Morb Mortal Wkly Rep 1993, 42:111–113.
66. Ling LJ, Hornfeldt CS, Winter JP: Absorption of iron after experimental overdose of chewable vitamins. Am J Emerg Med 1991, 9:24–26. DOI: 10.1016/0735-6757(91)90007-7
67. Robotham JL, Troxler RF, Lietman PS: Iron poisoning: another energy crisis. Lancet 1974, 2:664–665. DOI: 10.1016/S0140-6736(74)91999-0
68. Cheney K, Gumbiner C, Benson B, Tenenbein M: Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine. Clin Toxicol 1995, 33:61–66.
69. Ellenhorn MJ, Shonwald S, Ordog G, et al.: Metals and related compounds. In Ellenhorn’s Medical Toxicology, edn 2. Edited by Ellenhorn MJ. Baltimore: Williams & Wilkins; 1997:1559–1563.
70. Henretig FM, Temple AR: Acute iron poisoning in children. Clin Lab Med 1984, 3:575–586.
71. Everson GW, Oudjhane K, Young LW, Krenzelok EP: Effectiveness of abdominal radiographs in visualizing chewable iron supplements following overdose. Am J Emerg Med 1989, 7:459–463. DOI: 10.1016/0735-6757(89)90245-3
72. Toyokuni S, Sagripanti JL: Induction of oxidative single- and double-strand breaks in DNA by ferric citrate. Free Radic Biol Med 1993, 15:117–123. DOI: 10.1016/0891-5849(93)90050-5
73. Tomoda T, Kurashige T, Hayashi Y, et al.: Primary changes in liver damage by aspirin in rats. Acta Paediatr Jpn 1998, 40:593–596.
74. Zimmerman HJ: Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981, 141:333–342. DOI: 10.1001/archinte.141.3.333
75. Janota J, Wincey CW, Sandiford M, et al.: Effect of salicylate on the activity of plasma enzymes in the rabbit. Nature 1960, 185:935–936. DOI: 10.1038/185935a0
76. Zimmerman HJ: Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981, 141:333–342. DOI: 10.1001/archinte.141.3.333
77. Zimmerman HJ: Hepatic injury associated with nonsteroidal anti-inflammatory drugs. In Nonsteroidal Anti-inflammatory Drugs: Mechanism and Clinical Use. Edited by Lewis AJ, Furst DE. New York: Marcel Dekker; 1994:171–194.
78. Boelsterli UA, Zimmerman HJ, Kretz-Rommel A: Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanism and pathology. Crit Rev Toxicol 1995, 25:207–235.
79. Lewis JH: Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin Pharm 1984, 3:128–138.
80. Gitlin N: Salicylate hepatotoxicity: the potential role of hypoalbuminemia. J Clin Gastroenterol 1980, 2:281–285. DOI: 10.1097/00004836-198009000-00018
81. Lister-Melman ML, Hoofnagle J: Hepatotoxicity masked by corticosteroids. Arch Intern Med 1989, 149:1196–1197. DOI: 10.1001/archinte.149.5.1196
82. Zimmerman HJ: Hepatic injury associated with nonsteroidal anti-inflammatory drugs. In Nonsteroidal Anti-inflammatory Drugs: Mechanism and Clinical Use. Edited by Lewis AJ, Furst DE. New York: Marcel Dekker; 1994:171–194.
83. Seaman WE, Plotz PH: Effect of aspirin on liver tests in patients with RA and SLE and in normal volunteers. Arthritis Rheum 1976, 19:155–160. DOI: 10.1002/art.1780190205
84. Rich RR, Johnson JJ: Salicylate hepatotoxicity in patients with juvenile rheumatoid arthritis. Arthritis Rheum 1973, 16:1–9. DOI: 10.1002/art.1780160102
85. Gitlin N: Salicylate hepatotoxicity: the potential role of hypoalbuminemia. J Clin Gastroenterol 1980, 2:281–285. DOI: 10.1097/00004836-198009000-00018
86. Soller RW, Stander H: Association between salicylates and Reye’s syndrome. JAMA 1983, 249:883–884. DOI: 10.1001/jama.249.7.883
87. Meythaler JM, Varma RR: Reye’s syndrome in adults: diagnostic considerations. Arch Internal Med 1987, 147:61–64. DOI: 10.1001/archinte.147.1.61
88. Belay ED, Bresee JS, Holman RC, et al.: Reye’s syndrome in the United States from 1981 through 1997. N Engl J Med 1999, 340:1377–1382 DOI: 10.1056/NEJM199905063401801
89. Orlowski JP: Whatever happened to Reye’s syndrome? Did it really exist? Crit Care Med 1999, 27:1582–1587. This series of Reye’s syndrome patients from Australia suggests that the illness is more likely the result of an inborn error of ammonia metabolism rather than an interaction between aspirin and a viral illness. DOI: 10.1097/00003246-199908000-00032
90. Balistreri WF: Liver disease in infancy and childhood. In Schiff’s Diseases of the Liver, edn 8. Edited by Schiff ER, Sorrell MF, Maddrey WC. Philadelphia: Lippincott-Raven; 1999:1448–1460.
91. DeLeve LD, Kaplowitz N: Prevention and therapy of drug-induced hepatic injury. In Therapy of Digestive Disorders: A Companion to Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. Edited by Wolfe M. Philadelphia: WB Saunders; 2000:334–348.
92. Physicians’ Desk Reference 2000, edn 54. Montvale, NJ: Medical Economics; 2000.
93. Bourdi M, Masbuchi Y, Martin JL, et al.: Protection against acetaminophen-induced injury and lethality by IL-10: role of inducible nitric oxide synthase [abstract]. Proc Soc Toxicol 2001, in press.
94. Gruchalla RS: Clinical assessment of drug-induced disease. Lancet 2000, 356:1505–1511. DOI: 10.1016/S0140-6736(00)02885-3
95. Montanaro A: Sulfonamide allergy. Immunol Allergy Clin North Am 1998, 18:843–849. DOI: 10.1016/S0889-8561(05)70043-6
96. Mork H, al-Taie O, Klinge O, Scheurlen M: Successful therapy of persistent androgen-induced cholestasis with ursodeoxycholic acid. Z Gastroenterol 1997, 35:1087–1091.
97. O’Brien CB, Shields DS, Saul SH, Reddy R: Drug induced vanishing bile duct syndrome: response to ursodiol. Am J Gastroenterol 1996, 91:1456–1457.
98. Katsinelos P, Vasiliadis T, Xiarchos P, et al.: Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin) -induced intra-hepatic cholestasis: report of two cases. Eur J Gastroenterol Hepatol 2000, 12:365–368. DOI: 10.1097/00042737-200012030-00017
99. Lewis JH, Zimmerman HJ: Drug and chemical induced cholestasis. Clin Liver Dis 1999, 3:433–464. DOI: 10.1016/S1089-3261(05)70079-9
100. Lewis JH, Zimmerman HJ: Drug induced autoimmune liver disease. In Autoimmune Liver Disease, edn 2. Edited by Krawitt EL, Wiesner RH, Nishioka M. Amsterdam: Elsevier; 1998:627–649.
101. Singh C, Bishop P, Wilson R: Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: response to ursodeoxycholic acid treatment. Am J Gastroenterol 1996, 91:783–785.
102. Desmet VJ, van Eyken P, Roskams T: Histopathology of vanishing bile duct diseases. Adv Clin Path 1998, 2:87–99.
103. Siegel JH, Ramsey WH: Endoscopic biliary stent placement for bile duct stricture after hepatic artery infusion of 5-FUDR. J Clin Gastroenterol 1986, 8:673–676. DOI: 10.1097/00004836-198612000-00018
104. Kremer JM, Furst DE, Weinblatt ME, Blotner SD: Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996, 23:459–461.
105. Lewis JH: Monitoring for methotrexate hepatotoxicity in patients with rheumatoid arthritis: another hepatologist’s perspective. J Rheumatol 1997, 24:1459–1460.
106. Hashkes PJ, Balistreri WF, Bove KE, et al.: The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1999, 134:47–52. DOI: 10.1016/S0022-3476(99)70371-9
107. West SG: Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997, 23:883–915. DOI: 10.1016/S0889-857X(05)70365-3
108. Zachariae H: Liver biopsies and methotexate: a time for reconsideration? J Am Acad Dermatol 2000, 42:531–534. DOI: 10.1016/S0190-9622(00)90237-8
109. Buckley LM, Vacek PM, Cooper SM: Administration of folinic acid after low-dose methotrexate in patients with rheumatoid arthritits. J Rheumatol 1990, 17:1158–1161.
110. Morgan SL, Baggott JE, Vaughn WH, et al.: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994, 121:833–841.
111. Shiroky JB, Neville C, Esdaile JM, et al.: Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993, 36:1757–1758. DOI: 10.1002/art.1780361220
112. Ravelli A, Migliavacca D, Viola S, et al.: Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol 1999, 17:625–627.
113. Zachariae H, Sogaard H, Heickendorff L: Serum aminoterminal propeptide of type III procollagen: a non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Dermatol Venereol 1988, 69:241–243.
114. Boffa M, Smith A, Chalmers R, et al.: Serum type III procollagen aminopeptide for assessing liver damage in methotrexatetreated psoriatic patients. Br J Dermatol 1996, 135:538–544. DOI: 10.1046/j.1365-2133.1996.d01-1036.x
115. Zachariae H, Sogaard H, Heickendorff L: Methotrexateinduced liver cirrhosis, clinical, histological and serological studies: a further 10-year follow-up. Dermatology 1996, 192:343–346. DOI: 10.1159/000246408
116. vanDooren-GreebeR, Kuijpers A, Buijs W, et al.: The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br J Dermatol 1996, 134:481–487. DOI: 10.1046/j.1365-2133.1996.35790.x
117. McHenry P, Bingham E, Callender M, et al.: Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity. Br J Dermatol 1992, 127:122–125. DOI: 10.1111/j.1365-2133.1992.tb08043.x
118. Muntane J, Rodriguez FJ, Segado O, et al.: TNF-alpha dependent production of inducible nitric oxide is involved in PGE(1) protection against acute liver injury. Gut 2000, 47:553–562. DOI: 10.1136/gut.47.4.553
119. Deaciuc IV, Nikolova-Karakashian M, Fortunato F, et al.: Apoptosis and dysregulated ceramide metabolism in a murine model of alcohol-enhanced lipopolysaccharide hepatotoxicity. Alcohol Clin Exp Res 2000, 24:1557–1565. DOI: 10.1111/j.1530-0277.2000.tb04575.x
120. Diehl AM: Cytokine regulation of liver injury and repair. Immunol Rev 2000, 174:160–171. DOI: 10.1034/j.1600-0528.2002.017411.x
121. Hentze H, Gantner F, Kolb SA, Wendel A: Depletion of hepatic glutathione prevents death receptor-dependent apoptotic and necrotic liver injury in mice. Am J Pathol 2000, 156:2045–2056.